T-Therapeutics: Funding, Investors & Team (Sep 2026)
T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge.
T-Therapeutics has raised $32.0M across 1 funding round on record, the most recent a Series A of $32.0M announced in Nov 2025.
That round is above the $15M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
T-Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2025.
T-Therapeutics Funding Rounds
T-Therapeutics Founders and Leadership Team
Contact details for the T-Therapeutics team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →T-Therapeutics Funding Compared to Other Biotechnology Startups
T-Therapeutics' latest round of $32.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like T-Therapeutics in Biotechnology and Cambridge
Companies Similar to T-Therapeutics
Treating the seeds of cancer
Nuclide Therapeutics provides radiopharmaceutical medicines that combine nuclear medicine and biotechnology.
Cartography is an oncology company that develops cancer immunotherapies that target novel and highly specific…
Repair Biotechnologies is a biotechnology company developing therapies based on the cholesterol-degrading…
Ventuno Biotech is a biotech company that is developing innovative cancer therapies.
Skeletalis develops precision medicines targeting bone loss to treat osteoporosis and prevent fractures…
Azalea Therapeutics is a biotechnology company with a primary focus on developing cancer immunotherapies.
Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the…
Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and…
Adaptam Therapeutics is at the forefront of next-generation cancer immunotherapies
Excellergy develops portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe…
Curadel Surgical Innovations oversees the complete process of Curadel's FLARE contrast agents for…
T-Therapeutics Funding FAQs
What does T-Therapeutics do?
T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge.
How much funding has T-Therapeutics raised?
T-Therapeutics has raised $32.0M across 1 round on record. The most recent is a Series A of $32.0M announced in Nov 2025.
When did T-Therapeutics last raise funding?
T-Therapeutics' most recent funding round on record is a Series A of $32.0M, announced in Nov 2025.
Where is T-Therapeutics headquartered?
T-Therapeutics is based in Cambridge, United Kingdom.
How many employees does T-Therapeutics have?
T-Therapeutics is in the 51-100 employee band.
How does T-Therapeutics' funding compare to other Biotechnology startups?
T-Therapeutics' latest round of $32.0M is above the $15M median round size for Biotechnology companies on FundedIQ across 16 tracked companies over the last two years.
About FundedIQ's T-Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for T-Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.